Case Study: Protocol MRNA-1273-P204
A Phase 2/3 Study to Evaluate Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 to healthy Children
Study Objectives and Results
Objectives
- Global Enrollment Goal: 13,575 Participants
- QCR Enrollment Goal: 50 Participants
- Enrollment Window: 10 Months
- Target Population: Children < 12 Years
- Disease Characteristics: Participant in Good Health Based on Screening Physical Exam
Quality Clinical Research achieved its enrollment goal within the first month. Given this success, QCR was authorized to enroll beyond its initial target. This study had competitive enrollment and QCR outpaced average site enrollment. QCR’s contribution underscored its ability to exceed ambitious enrollment goals, reflecting its operational excellence.
Quality Clinical Research was the first site to vaccinate a child in this study.
Result 01
245 Patients Enrolled
Result 02
1.8% of Trial Population
Result 03
Outpaced Average Site Enrollment
